Physician profile
Hannah Schmidt
NPI 1801500988
$6,042.34
in general payments reported to CMS, 2019-2025
55 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,307 · 2024: $2,590 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,028 · Education: $1,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.30 |
| Education | $1,014.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $590.29 | 2023-2025 | |
| Janssen Biotech, INC. | $487.95 | 2024-2025 | Darzalex, Talvey, Erleada |
| Novartis Pharmaceuticals Corporation | $458.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $348.43 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Incyte Corporation | $341.28 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| Lilly USA, LLC | $331.14 | 2023-2025 | Retevmo, Verzenio, Jaypirca |
| Genentech USA, INC. | $328.46 | 2023-2025 | Phesgo, Itovebi, Polivy |
| Gilead Sciences, INC. | $311.96 | 2023-2025 | Trodelvy |
| Abbvie INC. | $224.14 | 2024-2025 | |
| Glaxosmithkline, LLC. | $210.97 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $148.69 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Celgene Corporation | $148.56 | 2023-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $134.84 | 2023-2024 | Imdelltra (Amg 757), Kyprolis, Blincyto |
| Daiichi Sankyo INC. | $127.76 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $120.81 | 2023-2024 | Fotivda |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $116.62 | 2024-2025 | |
| Tersera Therapeutics LLC | $108.83 | 2024-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $107.18 | 2023-2025 | Onivyde, Tazverik |
| Genmab U.S., INC. | $100.08 | 2023-2025 | Tivdak, Epkinly |
| Genzyme Corporation | $88.30 | 2023-2025 | |
| Stemline Therapeutics INC. | $88.19 | 2023-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $71.65 | 2023 | Myrisk |
| Genentech, INC. | $68.34 | 2024 | Alecensa, Tecentriq |
| Sumitomo Pharma America, INC. | $67.32 | 2024-2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $62.40 | 2024-2025 | Libtayo |
| Agios Pharmaceuticals, INC. | $57.09 | 2023-2025 | Pyrukynd |
| Sobi, INC | $54.50 | 2024-2025 | |
| Exelixis INC. | $50.85 | 2024 | Cabometyx |
| Eisai INC. | $49.49 | 2024 | |
| Springworks Therapeutics, INC. | $48.71 | 2024-2025 | Ogsiveo |
| Taiho Oncology, INC. | $42.71 | 2023-2025 | |
| Spectrum Pharmaceuticals INC. | $41.80 | 2024-2025 | Rolvedon |
| E.R. Squibb & Sons, L.L.C. | $33.95 | 2025 | Opdualag, Opdivo |
| Beone Medicines USA, INC. | $32.64 | 2025 | Tevimbra |
| Emd Serono, INC. | $31.14 | 2023 | Bavencio |
| Alkermes, INC. | $29.47 | 2025 | Vivitrol |
| Amneal Pharmaceuticals LLC | $28.78 | 2023 | Neupogen, Avastin, Neulasta |
| Iovance Biotherapeutics, INC. | $28.56 | 2025 | Amtagvi |
| Apellis Pharmaceuticals, INC. | $26.52 | 2023 | Empaveli |
| Pharmacosmos Therapeutics INC. | $22.89 | 2023 | Monoferric |
| Azurity Pharmaceuticals, INC. | $22.78 | 2025 | Danziten |
| Geron Corporation | $22.08 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $21.60 | 2024 | Krazati |
| Kyowa Kirin, INC. | $20.13 | 2023 | Poteligeo |
| Legend Biotech USA INC. | $20.10 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $20.00 | 2024 | |
| Rigel Pharmaceuticals, INC. | $18.54 | 2024 | Tavalisse, Rezlidhia |
| Seagen INC. | $17.03 | 2023 | Padcev |
| Immunocore Limited | $16.19 | 2025 | Kimmtrak |
| Alnylam Pharmaceuticals INC. | $16.14 | 2024 | Amvuttra |
| Fresenius Kabi USA, LLC | $16.11 | 2025 | Stimufend |
| Acrotech Biopharma INC. | $15.54 | 2025 | Beleodaq |
| Dendreon Pharmaceuticals LLC | $14.97 | 2025 | Provenge |
| G1 Therapeutics, INC. | $14.84 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $14.36 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.